
Keywords: cholinergic antagonists; urinary bladder; overactive; administration; intravaginal; women; clinical trialAE, adverse event; CNS, central nervous system; ER, extended release; OAB, overactive bladder; Oxy, oxybutynin; TEAEs, treatment emergent adverse even